Newron Pharmaceuticals S.p.A. (0QOI.L)
| Previous close | 2.4500 |
| Open | 1.5780 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.5780 - 1.5780 |
| 52-week range | 1.5780 - 1.5780 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 21.269M |
| Beta (5Y monthly) | 0.86 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.1430 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
Change in Newron Board of Directors
Newron Pharmaceuticals SpA / Key word(s): Personnel01-Dec-2021 / 17:46 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRMilan, Italy - Dec. 1, 2021 - Newron Pharmaceuticals S.p.A. ('Newron', SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today annou
- EQS Group
Newron Receives Fifth Tranche from Financing Agreement with European Investment Bank (EIB)
Newron Pharmaceuticals SpA / Key word(s): Financing18-Oct-2021 / 17:45 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 SIX Listing RulesMilan, Italy - October 18, 2021, 5:45 pm CEST - Newron Pharmaceuticals S.p.A. ('Newron') (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peri
- Business Wire
Newron Announces Half-Year 2021 Results
MILAN, September 16, 2021--Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5) today announces its operational and financial results for the half-year ended June 30, 2021.
